Cullinan Oncology reports Q3 net loss $24.9M; initiates pivotal zipalertinib study

Cullinan Therapeutics, Inc.

2022-Q3 EPS reported $2.96

Initiated pivotal study for zipalertinib in EGFR exon 20 NSCLC; cohort to evaluate 150 mg BID with food.
Increased ownership in MICA (CLN-619) from 54% to 92% for $30.7M cash.
Cash and investments $606.7M at Sept 30, 2022; runway extends beyond key milestones.
Net loss before noncontrolling interest $24.9M; R&D expenses $19.7M, G&A $10.1M.
Appointed Jacquelyn Sumer as CLO and Dr. David Ryan to Board; IND filings for CLN-617, CLN-978 on track for H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cullinan Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, Cullinan Oncology, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-283667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.